MindLinc Global Database (MGD)

The largest longitudinal de-identified psychiatry outcome database, with data from more than 500,000 patients collected during 20 million visits (7 million with outcome measurements) to approximately 30 organizations in the U.S.

MGD by the Numbers


Longitudinal data of >500,000 patients, with 50,000 patients being added annually

7,000,000 Qualified Clinical Visits (QCV) collected over 16 years

300 million rows of data with patient features

Robust Data on Diagnoses and Symptoms, Mental Health Status signs, Clinical Global Impressions (CGI), medications, side-effects and substance abuse data

MGD Data Source


Collected from 32 organisations from Academic Medical Centers (25%), Community Health Centers (50%) and Private Practices (25%)

Covers Outpatient, Inpatient and ER

MGD Data Features


Fully HIPAA compliant

Integration with regulatory management and research and quality management for psychiatric care

Clinical Decision Support Engine (CDSE)

Cohort analysis of most effective medication

Applications for MindLinc Data

Big Pharma

  • Treatment prediction for depression – using individual patient data from MindLinc
  • Use of data to see the effect of pharmaceutical company's marketing efforts and effective penetration, segregated by geography and timing
  • Clinical phenotyping support with a focus on PTSD (post-traumatic stress disorder), schizophrenia and depression

CROs

  • Use of data to predict the efficacy of the prescribed combination of drugs for patients
  • Analysing side effects, benefit comparison and level of compliance

Large Tech Companies

  • Extending it to clinic decision support tools where treatment algorithms are available
  • Analysing patterns to see which medical conditions correlate with which psychiatric problem
  • Genetic & sensor phenotyping
  • Further extension into tele-psychiatry and primary care

Health Policy

  • Leveraging the dataset for trials with the National Institute of Drug Abuse (NIDA)
  • Supporting policy makers in mental health situational analysis and needs assessment

Illustrative Research Output Done with MGD

Use of augmentation agent for treating depression: Analysis of a psychiatric electronic medical record data set
Download Download
Substance use disorders & comorbid Axis I and II psychiatric disorders among young psychiatric patient: findings from a large electronic health records database
Download Download
Using electronic health records data to assess comorbidities of substance use and psychiatric diagnoses and treatment settings among adults
Download Download
Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders
Download Download
Cognitive Function in Late Life Depression Relationships to Depression Severity, Cerebrovascular Risk Factors and Processing Speed
Download Download
Cognitive Improvement Following Treatment in Late Life Depression Relationship to Vascular Risk and Age of Onset
Download Download
Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian Americans, Native
Download Download
Medical Commorbidity in a Bipolar Outpatient Clinical Population
Download Download
Prevalence of HIV Infection in a General Psychiatric Outpatient Population
Download Download
Prim Care Companion - The Effectiveness of Antidepressant Monotherapy in a Naturalistic Outpatient Setting
Download Download
Support for the Vascular Depression Hypothesis in Late-Life Depression
Download Download
VisualDecisionLinc: A visual analytics approach for comparative effectiveness-based clinical decision support in psychiatry
Download Download

Creators of MindLinc

Dr. Ranga Krishnan

Dr. Krishnan has been serving as the new dean of Rush Medical College and senior vice president of Rush University Medical Center since August 2015. A key decision-maker in the Singapore biomedical sciences community, Dr Krishnan has been the Chairman of the National Medical Research Council (NMRC) since 2013. In early 2014 he was appointed the Chairman of the NMRC Singapore Translational Research Investigator Award (STaR) Panel. He is also Chairman of the Board of Directors of the Singapore Clinical Research Institute at the Ministry of Health (MOH), and holds memberships on board of the Health Sciences Authority, and Singapore Health Services Pte Ltd (SingHealth).

He is also a member of several committees:the Applied Study in Polytechnic and ITE Review (ASPIRE) Committee; the Biomedical Sciences Review Panel and the Biomedical Sciences Executive Committee, National Research Foundation (NRF).Prior to his Singapore move, Dr Krishnan was Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina for eleven years.

Kenneth Gersing

Ken Gersing, MD, is the Director of Clinical Information Services in the Department of Psychiatry at Duke University Medical Center. Dr. Gersing has a faculty appointment within the Department of Psychiatry and Behavioral Health at Duke. He holds a diploma in Psychiatry, and Dr. Gersing is board-certified by the American Board of Psychiatry and Neurology. Dr. Gersing completed his medical degree at the University of Washington, School of Medicine in 1993, and his psychiatric residency at Duke University Medical Center in 1997. He has 24 years of experience in medical information systems and clinical practice.